Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (DRKS00041882) titled 'A multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on burdensome body areas in patients with moderate-to-severe atopic dermatitis - the ADimpact study' on Oct. 9.
Study Type: observational
Study Design:
Allocation:
Masking:
Control:
Assignment:
Study design purpose: treatment
Primary Sponsor: Almirall S.A.
Condition:
L20
Atopic dermatitis
Intervention:
Group 1: To evaluate the impact of lebrikizumab on dermatology-related quality of life, as measured by the DLQI in the adult population and by cDLQI in the adolescent population, in patients with moderate-to-sev...